Needham & Company Raises PT on Hyperion Therapeutics (HPTX) to $25 after FDA Approval for Ravicti
Tweet Send to a Friend
Needham & Company raised its price target on Buy-rated Hyperion Therapeutics (NASDAQ: HPTX) from $15 to $25 after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
